We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Moleculin Biotech Inc | TG:MOL | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
From Jul 2019 to Jul 2024
By Sarka Halas
Hungarian oil company MOL Nyrt. (MOL.BU) has set pricing on its dollar-denominated, benchmark-sized seven-year bond at around the low 500 basis points over midswaps, one of the banks running the deal said Wednesday.
Citigroup and HSBC are the lead managers on the deal.
The issuer is rated BB+ by Moody's Investor Services and BBB- by Fitch Ratings.
Write to Sarka Halas at sarka.halasova@dowjones.com
1 Year Moleculin Biotech Chart |
1 Month Moleculin Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
